GSK has announced that the European Medicines Agency (EMA) has accepted the regulatory application to extend the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 18 years and older.

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older, and for people aged 50 to 59 years.

RSV is a common contagious virus that affects the lungs and respiratory tract and affects approximately 64 million people of all ages worldwide each year.

A European regulatory decision on this submission is expected in H1 2026.


Copyright (c) 2025 CercleFinance.com. All rights reserved.